CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
- Ni, J
- Cozzi, P J
- Hao, J L
- Beretov, J
- Chang, L
- Duan, W
- Shigdar, S
- Delprado, W J
- Graham, P H
- Bucci, J
- Kearsley, J H
- Li, Y
Publication date
May 2014
DOI Publisher
Wiley ISSN
0270-4137 Citation count (estimate)
40Abstract
Prostate cancer (CaP) is the second leading malignancy in older men in Western countries. The role of CD44 variant 6 (CD44v6) in CaP progression and therapeutic resistance is still uncertain. Here, we investigated the roles of CD44v6 in CaP metastasis and chemo/radioresistance. Expression of CD44v6 in metastatic CaP cell lines, human primary CaP tissues and lymph node metastases was assessed using immunofluorescence and immunohistochemistry, respectively
Add to ORKG